Background
GVHD includes systemic immunosuppression and local therapy.1-4 Allogeneic HSCT. GVHD occurs when the donor stem cells attack the recipient host cells and is a major cause of ocular morbidity, immune deficiency and mortality. Treatment of GVHD includes systemic immunosuppression and local therapy.1-3

Methods

Case Presentation

History
Systemic
Ocular History
Medications
SKT Lemp
Examination
Fundus
Visual Acuity

Visual Acuity

Three months following initial insertion of the scleral lenses, the patient reports significant improvement in dry eye symptoms and quality of vision in both eyes. Clinically, there is marked improvement in VA, mild decrease in conjunctival injection and significant decrease in debris OU.

Right Eye

Central Vault

Left Eye

Central Vault

REFERENCES

7. Bita Asghari, OD, Chantelle Mundy, OD, FAAO. Scleral Lens for Management of Ocular Surface Disease in Chronic GVHD.